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O R I G I N A L A R T I C L E 
Highly Effective Regimen for Decolonization 
of Methicillin-Resistant Staphylococcus aureus Carriers 
M. Buehlmann, MD; R. Frei, MD; L. Fenner, MD; M. Dangel, MPH; U. Fluckiger, MD; A. F. Widmer, MD, MS 
OBJECTIVE. To evaluate the efficacy of a standardized regimen for decolonization of methicillin-resistant Staphylococcus aureus (MRSA) 
carriers and to identify factors influencing decolonization treatment failure. 
DESIGN. Prospective cohort study from January 2002 to April 2007, with a mean follow-up period of 36 months. 
SETTING. University hospital with 750 beds and 27,000 admissions/year. 
PATIENTS. Of 94 consecutive hospitalized patients with MRSA colonization or infection, 32 were excluded because of spontaneous loss of 
MRSA, contraindications, death, or refusal to participate. In 62 patients, decolonization treatment was completed. At least 6 body sites were 
screened for MRSA (including by use of rectal swabs) before the start of treatment. 
INTERVENTIONS. Standardized decolonization treatment consisted of mupirocin nasal ointment, chlorhexidine mouth rinse, and full-body 
wash with chlorhexidine soap for 5 days. Intestinal and urinary-tract colonization were treated with oral vancomycin and cotrimoxazole, 
respectively. Vaginal colonization was treated with povidone-iodine or, alternatively, with chlorhexidine ovula or octenidine solution. Other 
antibiotics were added to the regimen if treatment failed. Successful decolonization was considered to have been achieved if results were negative 
for 3 consecutive sets of cultures of more than 6 screening sites. 
RESULTS. The mean age (± standard deviation [SD]) age of the 62 patients was 66.2 ± 19 years. The most frequent locations of MRSA 
colonization were the nose (42 patients [68%]), the throat (33 [53%]), perianal area (33 [53%]), rectum (36 [58%]), and inguinal area (30 
[49%]). Decolonization was completed in 87% of patients after a mean (±SD) of 2.1 ± 1.8 decolonization cycles (range, 1-10 cycles). 
Sixty-five percent of patients ultimately required peroral antibiotic treatment (vancomycin, 52%; cotrimoxazole, 27%; rifampin and 
fusidic acid, 18%). Decolonization was successful in 54 (87%) of the patients in the intent-to-treat analysis and in 51 (98%) of 52 patients 
in the on-treatment analysis. 
CONCLUSION. This standardized regimen for MRSA decolonization was highly effective in patients who completed the full decolonization 
treatment course. 
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In past decades, methicillin-resistant Staphylococcus aureus and outbreaks among injection drug abusers, prisoners, homeless 
(MRSA) has become the most important multidrug-resistant individuals, sports teams, and children in day care centers.5,6 
pathogen worldwide, causing significant morbidity and increased Studies of surgical patients colonized with methicillin-
healthcare costs.1,2 MRSA colonization precedes MRSA infection, susceptible S. aureus have demonstrated that decolonization 
which occurs in 20%-60% of colonized patients in acute-care treatment—for example, with mupirocin—can reduce the in-
facilities and in 3%-15% of those in long-term-care facilities.3 The cidence of subsequent infection.7 In addition, most authorities 
rate of nosocomial transmission of MRSA in healthcare facilities recommend that MRSA carriers be decolonized in outbreak 
can be reduced by the use of strict infection-control measures, situations. 
such as establishment of MRSA surveillance; early identification MRSA decolonization may reduce the risk of MRSA infec-
of carriers; isolation of colonized or infected patients; use of bar- tion in individual carriers and could prevent MRSA spread in 
rier precautions, such as use of gloves, gowns, and masks, for pa- healthcare facilities and in the community by eliminating a 
tient care; use of strict hand hygiene with alcohol-based hand reservoir for the organism. Several topical and systemic anti-
rubs; and careful environmental cleaning in patient rooms.3,4 Re- microbial agents have been used for MRSA decolonization, 
cently, community-associated strains of MRSA have begun to with limited success rates.811 However, most of the studies are 
spread in the community, causing intrafamily clusters of infection limited by the selection of patients (such as when patients with 
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MRSA infection are excluded), small sample sizes, and meth-
odological flaws.8 Therefore, the effectiveness of MRSA decol-
onization is still controversial, and it is not routinely recom-
mended. 
The present study was performed to evaluate the efficacy of 
a standardized MRSA decolonization treatment regimen for 
MRSA-colonized and MRSA-infected patients and to identify 
factors influencing the failure of the decolonization program. 
M E T H O D S 
Setting 
The University Hospital Basel is a primary- and tertiary-care 
center with 750 beds and 27,000 admissions/year. Since 1993, 
data on all patients colonized or infected with MRSA have been 
prospectively collected by use of case report forms and entered 
into a database. The local prevalence of methicillin resistance 
among S. aureus isolates has remained low (less than 5%) dur-
ing the past decade.12 Screening for MRSA by analysis of nose 
and throat swab samples is routinely performed for patients 
who (1) are transferred from areas with MRSA endemicity, (2) 
have a history of MRSA colonization, (3) have a history of 
injection drug use, or (4) have been in contact with a known 
MRSA carrier. 
Study Design and Definitions 
We conducted a prospective cohort study from January 1, 
2002, to April 30,2007. All patients admitted to the University 
Hospital who were colonized or infected with MRSA were eli-
gible for decolonization treatment. Patients who were unable 
or failed to attend follow-up visits were excluded from the 
analysis. For the purpose of the present study, MRSA coloni-
zation was defined as being present in any patient from whom 
MRSA was cultured from any body site (from routine screen-
ing or clinical specimens). MRSA infections were defined by 
use of the criteria of the Centers for Disease Control and Pre-
vention.13 
In an adaptation of the Centers for Disease Control and Pre-
vention definition, a case of MRSA colonization was defined as 
"community acquired" if the patient had (1) no history of 
MRSA colonization; (2) no history of hospitalization, surgery, 
or hemodialysis in the previous 12 months; and (3) an MRSA 
strain that was not epidemiologically linked to the hospital 
strains. A case was defined as "healthcare associated" if the 
patient (1) underwent hospitalization in an acute-care or long-
term-care facility, hemodialysis, or any surgery in the previous 
12 months and (2) had an MRSA strain that was epidemiolog-
ically not linked to the hospital strains. A case was defined as 
"nosocomial" if the patient had MRSA colonization diagnosed 
more than 48 hours after hospital admission, 30 days after an 
operation, or 1 year after implantation of persistent foreign 
body material (eg, a joint prosthesis). 
Decolonization 
Before initiation of decolonization treatment, all patients with 
MRSA colonization underwent standardized screening, using 
samples collected by use of polyester fiber-tipped swabs from 
the following body sites: the nose, throat, inguinal area, peri-
neal area, rectum, vagina (in women), wounds, and insertion 
sites of catheters. In addition, urine culture for MRSA was per-
formed for patients with urinary catheters or urinary-tract in-
fection. 
Decolonization treatment was offered to all patients. It con-
sisted of a 5-day standard regimen of application of mupirocin 
ointment (Bactroban; GlaxoSmithKline) twice daily, oral rins-
ing with 0.2% chlorhexidine solution (Dentohexin; Streuli 
Pharma) 3 times daily, and daily body washing with 4% chlor-
hexidine soap (Lifoscrub; B. Braun). In addition, specific de-
colonization treatment was administered for urogenital and 
gastrointestinal colonization: for patients with MRSA coloni-
zation of the urine, cotrimoxazole (800/160 mg twice daily) 
was administered for 5 days, if the strain was susceptible. For 
gastrointestinal colonization (indicated by an MRSA-positive 
rectal swab sample), oral vancomycin (1 g twice daily) was 
administered for 5 days. Vaginal colonization was treated with 
a povidone-iodine ovula (Betadine; Mundipharma Medical 
Company) administered once daily for 5 days as a first choice 
or, alternatively, a hexetidine ovula (Vagi-Hex; Drossapharm) 
administered twice daily for 6 days or octenidine solution (Oc-
tenisept; Schiilke & Mayr) twice daily for 6 days for patients 
who did not tolerate or had contraindications for the use of a 
povidone-iodine ovula. 
If a first cycle of decolonization treatment failed, the man-
agement of treatment was evaluated for potential obstacles to 
success—for example, noncompliance. Thereafter, a second 
cycle was started with the same regimen as described above. 
Systemic antibiotic treatment was recommended for patients 
whose conditions did not respond to 2 full cycles of decoloni-
zation treatment. Such patients were treated with fusidic acid 
(500 mg 3 times daily) and rifampin (450 mg twice daily) for 5 
days. Other antibiotics were chosen on an individual basis for 
patients colonized with MRSA strains resistant to fusidic acid 
or rifampin. 
MRSA decolonization was considered to be successful if 
there was no growth in 3 sets of surveillance cultures of samples 
(from the nose, throat, inguinal area, perianal area, rectum, 
vagina [in women], wounds, insertion sites, or urine [for pa-
tients with urinary-tract colonization]) obtained at least 2-3 
days after completion of decolonization treatment at intervals 
of 2-3 days. After successful MRSA decolonization, follow-up 
cultures (of nose and throat samples) were performed at every 
subsequent hospital admission. All patients ever colonized 
with MRSA are labeled in the hospital mainframe system, and 
an alarm is sent to the department of hospital epidemiology 
within minutes after admission. 
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21 excluded 
7 deaths (1 related to MRSA) 
1 complete screening 
7 noncompliance 
6 contraindications 
11 loss of MRSA 
5 spontaenous loss 
6 after treament of MRSA infection i 
8 decolonizations not successful 
4 infections 4 colonizations 
3 not completed 4 not completed 
1 failure 
10 recolonizations with MRSA 
1 infection 9 colonizations 
1 same strain 7 same strain 
1 other strain 
1 unknown 
94 MRSA colonization or infection 
cases in hospitalized patients 
62 patients 
with decolonization 
54 patients with 
successful decolonization 
13 infections 41 colonizations 
44 patients with 
long-term success 
12 infections 32 colonizations 
FIGURE i. Diagram summarizing inclusion and exclusion of patients in the study. MRSA, methicillin-resistant Staphylococcus aureus. 
Identification of MRSA and Molecular Typing 
MRSA screening was performed by means of culture in a 
highly selective enrichment broth, as described elsewhere.12 At 
the University Hospital Basel, each nonrepetitive clinical 
MRSA isolate has been typed by pulsed-field gel electrophore-
sis (PFGE) since 1993 and saved at — 70°C. In addition, strains 
have been typed by polymerase chain reaction (PCR)14 and, 
more recently, by spa typing.15 For the present study, MRSA 
isolates were thawed from frozen storage and subcultured 
twice. DNA was extracted by use of the LC MagnaPure system 
(Roche Diagnostics), in accordance with the manufacturer's 
instructions. Genes for Panton-Valentine leukocidin (pvl); 
toxic shock syndrome toxin (tsst); exfoliative toxins A, B, and 
D (eta, etb, and etd); and methicillin resistance (tnecA) were 
detected by PCR, as described elsewhere.1619 The polymorphic 
X region of the spa gene was amplified using primers spa-1113f 
and spa-1514r and sequenced as described elsewhere.15 Se-
quences were analyzed by use of StaphType software, version 
1.5.4, and SpaServer (both Ridom).20 Analysis of clustering 
into spa clonal complexes (spaCCs) was done using default 
parameters. Susceptibility to mupirocin was determined by 
E-test (AB Biodisk) and interpreted according to the commonly 
used definition (minimum inhibitory concentration for low-level 
resistance, 4-256 tig/mL; minimum inhibitory concentration for 
high-level resistance, more than 512 ju-g/mL).21'22 
Statistical Analysis 
Data were analyzed with SPSS version 14.0.1 for Windows 
(SPSS). Kaplan-Meier curves were used to describe the 
probability of decolonization success; covariates were com-
pared using the log rank test. P < .05 was considered to be 
significant. 
R E S U L T S 
During the study period, 94 cases of MRSA colonization or 
infection in hospitalized patients were identified, correspond-
ing to prevalences of 0.1 cases per 100 patients discharged and 
1.2 cases per 10,000 patient-days. Thirty-two cases were ex-
cluded from the analysis (Figure 1). For 11 patients, MRSA did 
not grow in screening cultures at the time when additional 
cultures were performed before decolonization was initiated, 
and all 11 patients had negative results for 3 sets of screening 
cultures at follow-up. 
The most common sites of MRSA colonization were the 
nose and throat (Table 1), and 36 patients (58%) had gastro-
intestinal MRSA colonization (positive rectal cultures). How-
ever, no patients were found to have MRSA colonization by 
rectal culture only. In addition, 6 (26%) of 23 women had 
vaginal colonization. Seventeen (27%) of the patients pre-
sented with MRSA infection (Table 1). A minority of patients 
had community-acquired MRSA colonization (Table 1). 
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TABLE 1. Demographic and Clinical Characteristics of Pa-
tients Colonized or Infected with Methicillin-Resistant Staph-
ylococcus aureus (MRSA) 
Characteristic Value 
No. of patients 
Male sex 
Age, years, mean ± SD 
Type of MRSA colonization 
Nosocomial 
Healthcare associated 
Community acquired 
spa type of colonizing strain {n = 56a) 
t041 
t008 
t002 
t032 
t030 
Otherb 
Site of colonization 
Nose 
Throat 
Inguinal area 
Perianal area 
Rectum 
Wound 
Urine 
Vagina1 
Otherd 
Risk factors for colonization 
Foreign-body implantation 
Chronic skin ulcer 
Diabetes mellitus 
Immunosuppression 
Hemodialysis 
Chronic skin disease 
None 
Site of MRSA infection 
Osteomyelitis or spondylodiscitis 
Bloodstream infection 
Skin and soft-tissue infection 
Pulmonary infection 
Other' 
Total no. of infections 
62 
39 (62.9) 
66.2 ± 19 
28 (45.2) 
27 (43.5) 
7(11.3) 
14(25) 
12 (21.4) 
7(12.5) 
5 (8.9) 
2 (3.6) 
16 (28.6) 
42 (67.7) 
33 (53.2) 
30 (48.8) 
33 (53.2) 
36(58.1) 
27 (43.5) 
13 (21.0) 
6(26) 
19 (30.6) 
19 (30.6) 
12 (19.3) 
8(12.9) 
5(8.1) 
2 (3.2) 
1 (1.6) 
15 (24.1) 
3 (4.8) 
3 (4.8) 
3 (4.8) 
2 (3.2) 
6 (9.7) 
17 (27.4) 
N O T E . Data are no. (%) of patients, unless otherwise indicated. 
a
 Six isolates were not available for spa typing. 
b
 Other spa types included tOOl, t016, t024, t025, t026, t037, t046, t074, 
tl508, U594, t230, t266, t355, t391, and t548. 
c
 Percentage of positive vaginal cultures among women only (6 of 23). 
d
 Insertion sites, 5 patients; blood, 4; sputum, 4; tracheobronchial se-
cretions, 1; tracheostoma, 1; abdomen, 1; penis, 1; subretinal fluid, 1; 
nasolacrimal duct, 1. 
' Prosthetic valve endocarditis, 1 patient; abdominal abscess, 1; uri-
nary tract infection, 1; dacryocystitis, 1; endophthalmitis, 1; foreign-
body infection, 1 (Tenkhoff catheter). 
Three isolates (5%) were positive for the community-acquired 
MRSA marker Panton-Valentine leukocidin, whereas the gene 
for toxic-shock syndrome toxin 1 was found in 3 other isolates. 
No isolate was positive for the exfoliative toxin gene. 
< (0 
a. 20-
• 1 site colonized 
2 2 sites colonized 
Number of Decolonization Courses 
F I G U R E 2. Number of decolonization courses needed for success-
ful methicillin-resistant Staphylococcus aureus (MRSA) eradication, 
overall (bold line) and stratified according to number of sites initially 
colonized by MRSA (P = .004). 
Overall, 54 of the patients (87%) were successfully decolo-
nized (intent-to-treat analysis). Of the 8 patients with decolo-
nization failure, 7 did not complete the decolonization 
treatment course according to the protocol, because of non-
compliance (3 patients) or sociomedical reasons (4 patients). 
The patient for whom decolonization failed despite comple-
tion of the decolonization treatment course was a young man 
who had been transferred to our hospital from Brazil after a car 
accident. After treatment of an open fracture, he developed a 
chronic osteomyelitis caused by multidrug-resistant Pseudo-
monas aeruginosa and was found to be colonized with MRSA 
(MRSA was not found in the bone biopsy). Treatment of os-
teomyelitis failed, as did decolonization after completion of 6 
decolonization treatment cycles. It was therefore decided to 
postpone further decolonization treatment until the osteomy-
elitis was under control. Treatment was successful in 51 (98%) 
of 52 (on-treatment analysis) of the patients who completed 
the full decolonization treatment cycle. 
For 29 (46.7%) of 62 of the patients, MRSA eradication was 
achieved after 1 decolonization course (Figure 2). A minority 
of patients (10 [16%]) underwent more than 3 decolonization 
courses. Patients with MRSA colonization at a single body site 
required significantly fewer decolonization courses for suc-
cessful eradication than did those with colonization at multiple 
sites (eradication rate after 1 course, 76.9% of patients with 1 
site colonized and 38.7% of patients with multiple sites colo-
nized; P = .004) (Figure 2). MRSA colonization persisted 
longer in patients with throat colonization than in patients 
with colonization of other sites (Figure 3). Decolonization 
was not successful in 23.5% of MRSA-infected patients, 
compared with 8.8% of colonized patients. Decolonization 
in patients with MRSA spa type t041 was more difficult to 
achieve than was decolonization in patients with other spa 
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F I G U R E 3. Number of patients colonized after each decolonization 
course (Deco), by methicillin-resistant Staphylococcus aureus coloni-
zation site (colonization of multiple sites was possible). 
types (eradication rate after 1 course, 26.6% and 51.2%, 
respectively); however, the difference was not statistically 
significant (P = .20). 
After successful decolonization, recolonization with MRSA 
occurred in 10 patients, after a mean interval of 240 days 
(range, 24-536 days). The recolonization isolate from 1 patient 
was not available for typing. One patient was colonized with a 
new MRSA type, confirmed by the presence of a new spa type 
(t008 and t032). In 8 patients, the recolonization strains were 
indistinguishable from the previous isolates by PFGE, a finding 
possibly indicating decolonization failure or recolonization by 
the identical strain. However, the long-term eradication rate 
was still 72.6%, under the assumption that all patients men-
tioned above are considered to have decolonization failure. A 
mean of 4 control screening cultures were available after suc-
cessful decolonization during a median follow-up period of 34 
months (range, 0-72 months). 
Mupirocin resistance was rare (Table 2). There was no 
mupirocin resistance observed in strains of MRSA from pa-
tients who were recolonized. 
Rates of susceptibility to rifampin, fusidic acid, and cotrimox-
azole were 92%, 83%, and 89%, respectively. No glycopeptide-
resistant MRSA strains were found. Of 62 isolates, 56 were avail-
able for spa typing. Of these, 40 (71.4%) belonged to 5 widely 
distributed epidemic spa types that are circulating throughout Eu-
rope (Table 1). 
D I S C U S S I O N 
Eradication of MRSA carriage may reduce the risk of infec-
tion in MRSA-colonized patients and prevent MRSA cross-
transmission to other individuals. However, the efficacy of 
MRSA decolonization treatment still remains controversial.8,9 
Our study demonstrates that MRSA decolonization with a 
combination of topical and systemic antimicrobial agents is 
highly effective for patients completing the full decolonization 
treatment course. Our decolonization success rate of 87% is 
higher than most rates that have been reported elsewhere in the 
literature.811 None of the previous studies defined decoloniza-
tion success as rigorously as ours: at least 6 body sites, some of 
them almost never screened in published studies (eg, the va-
gina), had to test negative by use of state-of-the-art selective 
enrichment broth methods.12 There are several possible rea-
sons for the high efficacy of our MRSA decolonization strategy. 
First, several other trials evaluated the efficacy of MRSA decol-
T A B L E 2. Characteristics of Methicillin-Resistant Staphylococcus 
aureus Decolonization in 94 Patients 
Characteristic Value 
Decolonization cycles required for successful 
decolonization, mean ± SD (range), no. per 
patient 
Time from diagnosis to start of first 
decolonization course, median (range), days 
Time to successful decolonization, median 
(range), days" 
Colonization with a mupirocin-resistant strain 
Low-level resistance (MIC, 4-256 jag/mL) 
High-level resistance (MIC3=512 /j,g/mL) 
Decolonization regimen 
Standardized regimen without antibiotics6 
Vancomycin by mouth 
Cotrimoxazole 
Rifampin plus fusidic acid 
Rifampin plus other antibiotic0 
Otherd 
Decolonization treatment result 
Successful decolonization 
Decolonization regimen not completed' 
Unsuccessful decolonization 
Follow-up period for successful 
decolonization, median (range), months 
N O T E . Data are no. (%) of patients, unless otherwise indicated. MIC, min-
imum inhibitory concentration. 
a
 Decolonization success was denned as 3 sets of negative culture results from 
swab samples from the following body sites: nose, throat, inguinal area, rec-
tum, perianal area, urine, wounds, and vagina (in women). 
b
 Application of mupirocin ointment twice daily, oral rinsing with chlorhexi-
dine 0.2% 3 times daily, and washing with chlorhexidine soap once daily for 5 
days. 
c
 Teicoplanine and rifampin, 1 patient; vancomycin and rifampin, 2 [1 of the 
2 courses was followed by treatment with cotrimoxazole and rifampin]. 
d
 Clindamycin, 1 patient; fusidic acid, 1; doxycyline, 1; linezolid, 1. 
' Interruption because of noncompliance for 3 patients and because of socio-
medical reasons for 4 patients. 
.1 ± 1.8(1-10) 
13 (0-687) 
65 (14-559) 
2 (3.6) 
1 (1.8) 
22 (35.5) 
32(51.6) 
17 (27.4) 
11 (17.7) 
3 (4.8) 
4 (6.4) 
54(87.1) 
7(11.3) 
1(1.6) 
34 (0-72) 
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onization on the basis of a single decolonization course. How-
ever, in our study, decolonization treatment was repeated if it 
was not successful at the first attempt, and possible reasons 
were evaluated, resulting in a mean of 2 courses per patient, 
with 16% of patients undergoing more than 3 decolonization 
courses. MRSA eradication after a single decolonization course 
was achieved in 46.7% of patients, which is comparable to rates 
in the literature.10,11'23'24 In pediatric patients with cystic fibro-
sis, a 3-step protocol with topical mupirocin, chlorhexidine for 
washing, and a 5-day course of rifampin and fusidic acid has 
been evaluated; MRSA eradication was achieved in 16 (94%) of 
17 patients—8 (47%) after 1 decolonization course and 8 
(47%) after 2 or 3 decolonization courses.25 Maraha et al.26 found 
the rate of MRSA elimination to be 100% after a mean of 1.6 
courses of treatment with enteral vancomycin and topical antimi-
crobials during an outbreak; decolonization was achieved after 1 
course in 69% of patients. 
Second, decolonization failure has been reported in patients 
colonized with MRSA strains with low-level mupirocin resis-
tance.23 In our study, the rate of low-level mupirocin resistance 
was low. Of 3 patients colonized with strains with low-level 
mupirocin resistance, 2 did not undergo decolonization be-
cause of noncompliance, and 1 patient was successfully decol-
onized. The only patient colonized with a strain with high-level 
mupirocin resistance did not complete decolonization because 
of noncompliance. In addition, decolonization failure or 
MRSA recolonization during follow-up was not associated 
with mupirocin resistance. 
Third, previous studies have revealed that the gastrointesti-
nal tract is an important MRSA reservoir in colonized pa-
tients.27,28 In our study, more than half of the patients had 
MRSA colonization of the gastrointestinal tract, as indicated 
by positive rectal cultures. Decolonization procedures using 
topical antimicrobial agents focus on eradication of MRSA on 
nares, skin, and, less frequently, the throat. However, treat-
ment is not targeted at gastrointestinal colonization, facilitat-
ing recolonization of other body sites. Silvestri et al.29 found 
eradication of MRSA gut carriage by treatment with enteral 
vancomycin to be effective in the reduction of the rate of 
MRSA colonization and infection in an outbreak among pa-
tients receiving mechanical ventilation in intensive care units. 
Maraha et al.26 reported a 100% success rate for MRSA decol-
onization with enteral vancomycin and topical antimicrobial 
treatment during an outbreak in a urological unit. In our 
study, elimination of gut carriage could have minimized the 
rate of decolonization failure and the risk of recolonization in 
our population. 
Recent studies have shown that the throat is an important 
site for MRSA colonization that can persist for years.12,30 Our 
data suggest that throat colonization is more difficult to erad-
icate than is colonization of other sites. One possible reason for 
this could be the insufficient levels of antiseptics that are 
achieved in the crypts of the tonsils with topical treatment. In 
addition, S. aureus can be internalized by human cells and can 
survive intracellularly.31 Systemic antibiotics, especially rifam-
pin and cotrimoxazole, may achieve better tissue and intracel-
lular levels,32 leading to higher MRSA eradication rates. How-
ever, this has to be confirmed in further studies. 
Countries such as The Netherlands also routinely decolo-
nize MRSA carriers. They report low prevalences of MRSA car-
riage, similar to those observed in our institution. We speculate 
that routine decolonization, which has been underestimated in 
the past as a strategy to control the spread of MRSA, may con-
tribute to the low prevalence. 
Our study has several limitations. It was not a random-
ized controlled trial; therefore, there was no appropriate 
control group. The study population consisted of a selected 
group of patients, 34% of whom did not meet inclusion 
criteria. This could have led to overestimation of the decol-
onization success. However, 27% of the patients were not 
only colonized but also infected with MRSA, which added 
obstacles to successful decolonization. The number of cases 
was small because of a low local MRSA prevalence. In fact, 
Switzerland has a very low rate of antibiotic use,33 leading to 
low selection pressure and potentially allowing MRSA to 
escape detection by screening culture. Finally, although the 
study design was prospective, with standardized protocols, 
PCR for the pvl and tsst genes and the additional method of 
spa typing were introduced during the study period. How-
ever, PFGE was used throughout the study. 
In conclusion, this standardized regimen including a com-
bination of topical and systemic antimicrobial agents was 
highly effective for MRSA decolonization in colonized and in-
fected individuals. The majority of patients were successfully 
decolonized with 2 or 3 decolonization courses. Decoloniza-
tion of patients with throat carriage seems to be more difficult 
to achieve than decolonization of patients with carriage at 
other sites, and systemic antibiotics may be necessary in the 
treatment of patients whose conditions do not respond to top-
ical therapy. Specific treatment of gastrointestinal and urogen-
ital MRSA reservoirs may improve the rate of successful decol-
onization. However, the evolution of other antibiotic-resistant 
organisms, such as vancomycin-resistant enterococci, needs to 
be carefully monitored. 
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